{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:45:01Z","timestamp":1794692701363,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jiac.2025.102735","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T23:49:45Z","timestamp":1747698585000},"page":"102735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of antibiotic adverse events"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9098-5960","authenticated-orcid":false,"given":"Toshiharu","family":"Urakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-0510","authenticated-orcid":false,"given":"Takashi","family":"Matono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102735_bib1","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102735_bib2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of adverse events with antibiotic use in hospitalized patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jiac.2025.102735_bib3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jiac.2018.11.002","article-title":"Antibiotic-associated adverse drug events at a Japanese academic hospital","volume":"25","author":"Kokado","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib4","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/jhm.414","article-title":"Incidence and impact of adverse effects to antibiotics in hospitalized adults with pneumonia","volume":"4","author":"Lin","year":"2009","journal-title":"J Hosp Med"},{"key":"10.1016\/j.jiac.2025.102735_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000441-198710000-00011","article-title":"Drug fever: mechanisms, maxims and misconceptions","volume":"294","author":"Mackowiak","year":"1987","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jiac.2025.102735_bib6","first-page":"85","article-title":"Drug fever","volume":"10","author":"Johnson","year":"1996","journal-title":"Infect Dis Clin"},{"key":"10.1016\/j.jiac.2025.102735_bib7","first-page":"149","article-title":"Antibiotic side effects","volume":"85","author":"Cunha","year":"2001","journal-title":"Med Clin"},{"key":"10.1016\/j.jiac.2025.102735_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1620\/tjem.159.45","article-title":"Clinical study of drug fever induced by parenteral administration of antibiotics","volume":"159","author":"Oizumi","year":"1989","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.jiac.2025.102735_bib9","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jiac.2025.102735_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jiac.2025.102735_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaip.2017.08.027","article-title":"Cross-reactivity in \u03b2-lactam allergy","volume":"6","author":"Zagursky","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jiac.2025.102735_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhin.2020.05.042","article-title":"Impact of penicillin allergy records on antibiotic costs and length of hospital stay: a single-centre observational retrospective cohort","volume":"106","author":"Powell","year":"2020","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jiac.2025.102735_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jama.2018.19283","article-title":"Evaluation and management of penicillin allergy: a review","volume":"321","author":"Shenoy","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2025.102735_bib14","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/cea.13044","article-title":"Enhancing antibiotic stewardship by tackling \u201cspurious\u201d penicillin allergy","volume":"47","author":"Krishna","year":"2017","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"10.1016\/j.jiac.2025.102735_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.09.015","article-title":"Retrospective study on penicillin allergy delabeling and evaluation of an antibiotic allergy assessment tool","volume":"31","author":"Honda","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/cid\/ciaa653","article-title":"The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study","volume":"73","author":"Chua","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamainternmed.2020.0403","article-title":"Development and validation of a penicillin allergy clinical decision rule","volume":"180","author":"Trubiano","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jiac.2025.102735_bib18","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2215\/CJN.07630717","article-title":"Drug-induced acute interstitial nephritis","volume":"12","author":"Moledina","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jiac.2025.102735_bib19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2025.102735_bib21","doi-asserted-by":"crossref","unstructured":"Yamada T, Fujii S, Shigemi A, Takesue Y. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity. J Infect Chemother 202;27:256\u2013261. https:\/\/doi.org\/10.1016\/j.jiac.2020.09.033.","DOI":"10.1016\/j.jiac.2020.09.033"},{"key":"10.1016\/j.jiac.2025.102735_bib22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jiac.2021.03.015","article-title":"Is trimethoprim\/sulfamethoxazole-associated increase in serum creatinine a pseudo-elevation or true nephrotoxicity?","volume":"27","author":"Urakami","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib23","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkr159","article-title":"Hepatic safety of antibiotics used in primary care","volume":"66","author":"Andrade","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib24","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jiac.2019.05.020","article-title":"Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder","volume":"25","author":"Ito","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib25","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med"},{"key":"10.1016\/j.jiac.2025.102735_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-214804","article-title":"Imipenem\/cilastatin-induced acute eosinophilic pneumonia","volume":"2016","author":"Foong","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jiac.2025.102735_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2021.e01166","article-title":"Eosinophilic pneumonia caused by cefepime: a case report and review","volume":"25","author":"Jones","year":"2021","journal-title":"IDCases"},{"key":"10.1016\/j.jiac.2025.102735_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: a review of 196 case reports","volume":"97","author":"Bartal","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jiac.2025.102735_bib29","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jinf.2006.11.006","article-title":"Eosinophilic pneumonia induced by daptomycin","volume":"54","author":"Hayes","year":"2007","journal-title":"J Infect"},{"key":"10.1016\/j.jiac.2025.102735_bib30","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s15010-024-02349-z","article-title":"Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series","volume":"52","author":"Gidari","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2025.102735_bib31","unstructured":"FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin). https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-eosinophilic-pneumonia-associated-use-cubicin-daptomycin [accessed 3 Augst 2017]."},{"key":"10.1016\/j.jiac.2025.102735_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/antibiotics11020254","article-title":"Factors associated with daptomycin-induced eosinophilic pneumonia","volume":"11","author":"Ishikawa","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jiac.2025.102735_bib33","first-page":"110","article-title":"Minocycline-induced acute eosinophilic pneumonia: a case report and review of the literature","volume":"15","author":"Hung","year":"2015","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jiac.2025.102735_bib34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1590\/s1806-37562018000000028","article-title":"Eosinophilic pneumonia: remember topical drugs as a potential etiology","volume":"44","author":"Dias","year":"2018","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.jiac.2025.102735_bib35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1164\/ajrccm.160.4.9901075","article-title":"Corticosteroids in acute respiratory failure","volume":"160","author":"Jantz","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2025.102735_bib36","first-page":"1058","article-title":"Rhabdomyolysis","volume":"144","author":"Zimmerman","year":"2013","journal-title":"Chest (Am Coll Chest Physicians)"},{"key":"10.1016\/j.jiac.2025.102735_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03473.x","article-title":"Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction","volume":"68","author":"Strandell","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102735_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216048","article-title":"Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis","volume":"2016","author":"Goldie","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jiac.2025.102735_bib39","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/cid\/ciac128","article-title":"Association between statin use and daptomycin-related musculoskeletal adverse events: a mixed approach combining a meta-analysis and a disproportionality analysis","volume":"75","author":"Chuma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib40","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/bcp.15172","article-title":"Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: a systematic review and meta-analysis","volume":"88","author":"Samura","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102735_bib41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy","volume":"67","author":"Dare","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib42","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1248\/bpb.b20-00217","article-title":"Evaluation of daptomycin-induced cellular membrane injury in skeletal muscle","volume":"43","author":"Yamada","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jiac.2025.102735_bib43","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/bcp.15063","article-title":"Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods","volume":"88","author":"Imai","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102735_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz444","article-title":"A retrospective multisite case-control series of concomitant use of daptomycin and statins and the effect on creatine phosphokinase","volume":"6","author":"Lehman","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab568","article-title":"Identification of risk factors for daptomycin-associated creatine phosphokinase elevation and development of a risk prediction model for incidence probability","volume":"8","author":"Samura","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib46","first-page":"504","article-title":"Rhabdomyolysis associations with antibiotics: a pharmacovigilance study of the FDA adverse event reporting system (faers)","volume":"16","author":"Teng","year":"2019","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jiac.2025.102735_bib47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/bcp.15671","article-title":"Comparison of the efficacy and safety of standard- and high-dose daptomycin: a systematic review and meta-analysis","volume":"89","author":"Samura","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102735_bib48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jiac.2019.01.011","article-title":"Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients","volume":"25","author":"Urakami","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib49","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib50","first-page":"714","article-title":"Practical guidelines for the management and treatment of infections caused by MRSA","volume":"87","author":"Niki","year":"2013","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.jiac.2025.102735_bib51","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7326\/0003-4819-101-1-92","article-title":"The neurotoxicity of antibacterial agents","volume":"101","author":"Snavely","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jiac.2025.102735_bib53","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jiac.2025.102735_bib54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1592\/phco.31.4.408","article-title":"Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations","volume":"31","author":"Miller","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2025.102735_bib55","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jac\/dku111","article-title":"The risk of seizures among the carbapenems: a meta-analysis","volume":"69","author":"Cannon","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/FTD.0000000000001138","article-title":"Dose individualization of cefepime for febrile neutropenia in patients with lymphoma or multiple myeloma: implications for therapeutic drug monitoring","volume":"46","author":"Oda","year":"2024","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2025.102735_bib57","article-title":"Metronidazole-induced encephalopathy","volume":"25","author":"Lala","year":"2021","journal-title":"SA J Radiol"},{"key":"10.1016\/j.jiac.2025.102735_bib58","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/cid\/cis664","article-title":"Fluoroquinolones and the risk of serious arrhythmia: a population-based study","volume":"55","author":"Lapi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102735_bib59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","article-title":"Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis","volume":"42","author":"Gorelik","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.jiac.2025.102735_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/asheducation-2009.1.153","article-title":"Drug-induced thrombocytopenia: pathogenesis, evaluation, and management","author":"George","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jiac.2025.102735_bib61","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"Marini","year":"2022","journal-title":"Haematologica (Roma)"},{"key":"10.1016\/j.jiac.2025.102735_bib62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcp.14965","article-title":"Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta\u2010analysis","volume":"88","author":"Shi","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2025.102735_bib63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2025.102735_bib64","article-title":"Antibiotic-induced neutropenia in patients receiving outpatient parenteral antibiotic therapy: a retrospective cohort study","volume":"67","author":"Lam","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102735_bib65","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1060028020975646","article-title":"A review of \u03b2-lactam-associated neutropenia and implications for cross-reactivity","volume":"55","author":"Cimino","year":"2021","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:03:32Z","timestamp":1749711812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1341321X25001321"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102735","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of antibiotic adverse events","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102735"}}